214193-12-1 Usage
Description
(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxylic acid is a chiral chemical compound with a unique fused bicyclic structure that contains a nitrogen atom. Its three stereocenters, indicated by the R and S notations, determine its spatial arrangement in three-dimensional space. As a carboxylic acid, it has a functional group composed of a carboxyl group (–COOH), which is important for its reactivity and ability to form salts and esters.
Uses
Used in Pharmaceutical Industry:
(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxylic acid is used as a building block for the synthesis of pharmaceutical compounds due to its unique structure and potential for modulating biological activity.
Used in Organic Synthesis:
(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxylic acid is used as an intermediate in the synthesis of various organic compounds, taking advantage of its reactivity and ability to form salts and esters.
Used in Stereochemical Research:
(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxylic acid is used as a model compound for studying stereochemical effects in chemical reactions and biological processes, given its three-dimensional shape and chiral nature.
Check Digit Verification of cas no
The CAS Registry Mumber 214193-12-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,1,9 and 3 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 214193-12:
(8*2)+(7*1)+(6*4)+(5*1)+(4*9)+(3*3)+(2*1)+(1*2)=101
101 % 10 = 1
So 214193-12-1 is a valid CAS Registry Number.
214193-12-1Relevant articles and documents
MASP INHIBITORY COMPOUNDS AND USES THEREOF
-
Page/Page column 154, (2020/11/23)
The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.